Scientific publications
A CD38/CD3xCD28 trispecific T-cell engager as a potentially active agent in multiple myeloma patients relapsed and/or refractory to anti-CD38 monoclonal antibodies. Scientific Publication
Aintzane Zabaleta 1 , Laura Blanco 1 , Peter S Kim 2 , Kamlesh Bisht 2 , Hongfang Wang 2 , Helgi Van de Velde 2 , Marta Lasa 1 , Luis-Esteban Tamariz-Amador 1 , Paula Rodriguez-Otero 1 , Jesús San-Miguel 1 , Bruno Paiva 1 , Esperanza Martín-Sánchez 1
Abstract
There is accumulating evidence of BCMA and GPRC5D loss after treatment with T-cell redirecting therapies in patients with relapsed/refractory multiple myeloma (RRMM).
While complete CD38 loss is not observed upon relapses after treatment with anti-CD38 monoclonal antibodies (mAb), there is downregulation of surface CD38 expression and decreased number and function of NK cells, which renders these patients resistant to retreatment with anti-CD38 mAb.
Here, we provide preclinical evidence that RRMM patients previously exposed to anti-CD38 mAb could benefit from T-cell-based immunotherapy that depend less on CD38 antigen density and NK-cell activity, such as the novel CD38/CD3xCD28 trispecific T-cell engager, SAR442257.
CITATION Br J Haematol. 2024 Sep 22. doi: 10.1111/bjh.19784
Our authors
